CELC NASDAQ
Celcuity Inc.
1W: +15.2%
1M: -17.2%
3M: -20.2%
YTD: -34.6%
1Y: -6.8%
3Y: +556.7%
5Y: +273.0%
$68.11
+2.31 (+3.51%)
After Hours: $67.98 (-0.12, -0.18%)
Weekly Expected Move ±8.8%
$54
$59
$65
$71
$77
Credit Risk of going bust: higher than 68% of companies Debt: 19.0% of company value Bonds: $29.4M held by 33 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.92 (down 97%), Celcuity Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $3.22B.
Distance to default 3.58 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $377.1M (short-term plus half of long-term), stock volatility 65.8%; Altman Z'' 1.75. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.92 (down 97%), Celcuity Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $3.22B.
Distance to default 3.58 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $377.1M (short-term plus half of long-term), stock volatility 65.8%; Altman Z'' 1.75. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Celcuity says Revtorpyk boosts progression-free survival in breast cancer
1,290,466 Celcuity, Inc. $CELC Shares Bought by Assenagon Asset Management S.A.
New Strong Sell Stocks for October 14th
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
12,476 Celcuity, Inc. $CELC Shares Purchased by Envestnet Asset Management Inc.
Most shorted stocks on Wall Street
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Why Celcuity Stock Was a Winner on Wednesday
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
12,027 Shares of Celcuity, Inc. $CELC Purchased by Corient Private Wealth LP
Bank of America Corp DE Makes New $153.93 Million Investment in Celcuity, Inc. $CELC
Most shorted stocks on Wall Street
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Brandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELC
Celcuity (CELC) Q2 2026 Earnings Call Transcript
Celcuity plans late Q3 2026 REVTORPYK shipments and targets sNDA submission in Q3 2026
California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC
Assenagon Asset Management S.A. Buys New Shares in Celcuity, Inc. $CELC
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
Celcuity falls as rollout concerns overshadow FDA approval of breast cancer drug
Celcuity gains approval of breast cancer therapy gedatolisib
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
What's Going On With Celcuity Stock On Tuesday?
12 Health Care Stocks Moving In Tuesday's Intraday Session
$CELC stock is down 23% today. Here's what we see in our data. - Quiver Quantitative
Celcuity slides 22.8% as investors digest new VIKTORIA-1 PIK3CA-mutant data - Quiver Quantitative
Leerink cuts Celcuity stock price target on trial results - Investing.com
Celcuity Crashes On Breast Cancer Disappointment. What Happened?
Celcuity posts trial data for breast cancer drug (CELC:NASDAQ) - Seeking Alpha
Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Celcuity stock tumbles 15% despite positive trial results - Investing.com
Will Celcuity Rocket On Its Newest Approach To Breast Cancer Treatment - Investor's Business Daily
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
Assessing Celcuity (CELC) Valuation As Investor Optimism And Conflicting Fair Value Views Intensify - simplywall.st
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Celcuity To Participate in Upcoming Investor Conferences
How Investors May Respond To Celcuity (CELC) Expanding VIKTORIA-2 And Pursuing Subcutaneous Gedatolisib - simplywall.st
Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Assessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA Decision
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst
Celcuity Inc (CELC) Q1 2026 Earnings Call Highlights: Promising Clinical Trials and Strategic ...
Celcuity outlines VIKTORIA-2 expansion while targeting July 17 FDA decision for gedatolisib
Celcuity Q1 Earnings Call Highlights
Celcuity (CELC) Q1 2026 Earnings Transcript
Celcuity (CELC) Q1 2026 Earnings Transcript
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
CELCUITY ($CELC) Releases Q1 2026 Earnings - Quiver Quantitative
Breast cancer trial widens as Celcuity develops injection option - Stock Titan
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Is It Too Late To Consider Celcuity (CELC) After Its Recent Share Price Surge? - simplywall.st
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge? - Yahoo Finance
Top Midday Gainers
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
12 Health Care Stocks Moving In Monday's Pre-Market Session
This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday
This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Packaging Corp Of America To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Why Is Celcuity Stock Rallying Today?
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Why Celcuity Stock Popped on Monday
Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments
Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments - Yahoo Finance
Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC
Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally - Yahoo Finance
Tudor Investment Corp ET AL Invests $1.35 Million in Celcuity, Inc. $CELC
Why Celcuity Stock Popped Today
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations
Celcuity Non-GAAP EPS of -$0.73 beats by $0.28
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Earnings Scheduled For March 25, 2026
CELCUITY ($CELC) Releases Q4 2025 Earnings | CELC Stock News - Quiver Quantitative
Apis Capital Advisors LLC Acquires New Holdings in Celcuity, Inc. $CELC
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
15,000 Shares in Celcuity, Inc. $CELC Purchased by Aristides Capital LLC
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Choreo LLC Takes Position in Celcuity, Inc. $CELC
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Soleus Adds a Significant Number of Celcuity Shares
Celcuity Appoints Charles Romp to its Board of Directors
AlTi Global Inc. Purchases New Shares in Celcuity, Inc. $CELC
Celcuity, Inc. $CELC Stake Boosted by New York State Common Retirement Fund
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump
Assessing Celcuity (CELC) Valuation After Recent Share Price Momentum And DCF Upside Estimate - Yahoo Finance
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026